AbbVie, BigHat partner to discover next-generation therapeutic antibodies
The research collaboration will leverage BigHat’s artificial intelligence and machine learning (AI/ML) guided Milliner platform and AbbVie’s expertise…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
06 Dec 23
The research collaboration will leverage BigHat’s artificial intelligence and machine learning (AI/ML) guided Milliner platform and AbbVie’s expertise…
06 Dec 23
Under the terms of this arrangement, the French pharmatech firm will use its deep physics and generative AI…
06 Dec 23
A comparison of the intent-to-treat population at eight years of follow-up with MONARCH 3 revealed that women taking…
06 Dec 23
The trial achieved progression-free survival (PFS) and showed a statistically significant and clinically meaningful improvement against palbociclib and…
06 Dec 23
The expansion marks a continuation of the established partnership between Oxford and Ionis, which began with Oxford's acquisition…
06 Dec 23
OVX836 has already been evaluated in several Phase 2 clinical trials against seasonal influenza with initial signals of…
06 Dec 23
Financing led by Ascenta Capital with participation from new and existing investors; Dr. Lorence Kim joins board of…
05 Dec 23
Through the acquisition, Roche will get access to Carmot’s portfolio of incretins, including its lead asset CT-388, along…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
05 Dec 23
Under the agreement, Merck has the license to commercialise products comprising or containing CSF-1R inhibitor for all indications…
05 Dec 23
The partnership combines AstraZeneca's expertise in oncology R&D with Absci's Integrated Drug Creation platform to expedite the discovery…